Ameriprise Financial Inc. Sells 4,600 Shares of Repligen Co. (RGEN)
Ameriprise Financial Inc. lessened its position in Repligen Co. (NASDAQ:RGEN) by 1.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 414,961 shares of the biotechnology company’s stock after selling 4,600 shares during the quarter. Ameriprise Financial Inc. owned approximately 1.22% of Repligen worth $15,902,000 as of its most recent filing with the SEC.
Other institutional investors have also recently made changes to their positions in the company. Quantbot Technologies LP acquired a new position in shares of Repligen during the 2nd quarter worth approximately $120,000. Oppenheimer Asset Management Inc. acquired a new position in shares of Repligen during the 2nd quarter worth approximately $123,000. Victory Capital Management Inc. increased its position in shares of Repligen by 17.7% during the 2nd quarter. Victory Capital Management Inc. now owns 4,001 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 601 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Repligen during the 3rd quarter worth approximately $180,000. Finally, Pinebridge Investments L.P. increased its position in shares of Repligen by 1.7% during the 2nd quarter. Pinebridge Investments L.P. now owns 4,491 shares of the biotechnology company’s stock worth $186,000 after purchasing an additional 76 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.
Repligen Co. (NASDAQ RGEN) opened at $35.23 on Friday. Repligen Co. has a one year low of $28.48 and a one year high of $46.81. The company has a market capitalization of $1,549.62, a P/E ratio of 61.33, a PEG ratio of 2.32 and a beta of 1.04.
Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, November 9th. The biotechnology company reported $0.15 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.11 by $0.04. Repligen had a return on equity of 7.57% and a net margin of 16.93%. The company had revenue of $36.58 million during the quarter, compared to the consensus estimate of $35.69 million. During the same period in the previous year, the company posted $0.08 EPS. The firm’s revenue for the quarter was up 48.2% compared to the same quarter last year. equities analysts expect that Repligen Co. will post 0.61 EPS for the current year.
Several research analysts have weighed in on RGEN shares. Jefferies Group reaffirmed a “hold” rating and set a $40.00 price target on shares of Repligen in a research report on Thursday, September 14th. Zacks Investment Research raised Repligen from a “hold” rating to a “buy” rating and set a $43.00 price target on the stock in a research report on Thursday, October 5th. CL King assumed coverage on Repligen in a research note on Monday, November 13th. They set a “buy” rating and a $41.00 target price for the company. TheStreet downgraded Repligen from a “b-” rating to a “c” rating in a research note on Monday, November 13th. Finally, First Analysis upgraded Repligen from an “equal weight” rating to an “overweight” rating and set a $47.00 target price for the company in a research note on Monday, October 2nd. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $44.38.
WARNING: “Ameriprise Financial Inc. Sells 4,600 Shares of Repligen Co. (RGEN)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.watchlistnews.com/ameriprise-financial-inc-sells-4600-shares-of-repligen-co-rgen/1765082.html.
Repligen Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with Analyst Ratings Network's FREE daily email newsletter.